FDA approves drug for treating postpartum depression
TRENTON, N.J. — The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth. The agency on Tuesday approved Sage Therapeutics' Zulresso, an IV drug given over 2 ½ days. Sage said Zulresso will cost $34,000 without insurance, plus costs for staying in a hospital or infusion center. Whether the treatment gets covered by insurance is determined by each insurance company, which also sets the out-of-pocket costs, depending on the plan.
Post to Tumblr